Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial
Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial. Arthritis Research & Therapy 2012, 14: r6. PMID: 22225620, PMCID: PMC3392792, DOI: 10.1186/ar3554.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArea Under CurveArthritis, RheumatoidChemokine CXCL13DiarrheaDose-Response Relationship, DrugDouble-Blind MethodFemaleHeadacheHumansInjections, IntravenousInjections, SubcutaneousLymphotoxin-alphaMaleMetabolic Clearance RateMiddle AgedSignal TransductionTreatment OutcomeYoung AdultConceptsRA patientsAdverse eventsDose phaseClinical activityBiologic activityMedian Disease Activity ScoreMajority of AEsLymphotoxin αACR70 response ratesActive RA patientsRA disease activityDisease Activity ScorePlacebo-controlled trialSerious adverse eventsRheumatoid arthritis (RA) pathogenesisC-reactive proteinNovel monoclonal antibodyDisease activityPlacebo groupArthritis pathogenesisSerum CXCL13Activity scoreClinical effectsMultiple dosesT cells